Skip to content

EV / EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
12×+0.4×
Incyte logo
IncyteINCY
-28.2×
Merck & Co. logo
Merck & Co.MRK
23.1×+11.7×
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.8×+4.2×
ALN
Alnylam PharmaceuticalsALNY
52.6×
Biogen logo
BiogenBIIB
11.2×+2.8×

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$155.75B+23.8%
Enterprise value$170.3B+19.7%
P/E16.9×-4.2×
P/S5.2×+0.9×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio+0.6×

Where this comes from

Calculated from Gilead Sciences’s reported figures.

Based on the most recent quarter.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's EV / EBITDA?
Gilead Sciences (GILD) reported EV / EBITDA of 17.5× in Q1 2026.
How has Gilead Sciences's EV / EBITDA changed year-over-year?
Gilead Sciences's EV / EBITDA decreased by 4.1% year-over-year, from 18.2× to 17.5×.
What is the long-term trend for Gilead Sciences's EV / EBITDA?
Over 4 years (2021 to 2025), Gilead Sciences's EV / EBITDA has grown at a 5.8% compound annual growth rate (CAGR), from 53.4× to 67.1×.
What does EV / EBITDA mean?
What the whole business (debt included) costs relative to its operating cash earnings.
How do you interpret EV / EBITDA?
Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
How does EV / EBITDA compare across companies?
Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.